Metagenomi Therapeutics (MGX) Common Equity (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Common Equity data on file, last reported at $137.8 million in Q1 2026.

• Common Equity for Q1 2026 came in at $137.8 million, down 35.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $137.8 million (down 35.21% YoY), and the FY2025 annual result was $158.6 million, down 32.47% from the prior year.
• Common Equity declined to $137.8 million in Q1 2026 per MGX's latest filing, from $158.6 million in the prior quarter.
• Over five years, Common Equity peaked at $275.6 million in Q1 2024 and troughed at -$135.6 million in Q4 2023.
• A 4-year average of $122.4 million and a median of $178.4 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2026: Common Equity surged 214997.37% in 2024, then sank 35.21% in 2026.
• A 4-year view of Common Equity shows it stood at -$135.6 million in 2023, then jumped by 273.22% to $234.9 million in 2024, then plunged by 32.47% to $158.6 million in 2025, then declined by 13.12% to $137.8 million in 2026.
• Business Quant data shows MGX's Common Equity at $137.8 million in Q1 2026, $158.6 million in Q4 2025, and $178.4 million in Q3 2025.